Workshop organized by Health Technologies / Cell biology, development and evolution / Immunology, hematology, pneumology ITMOS of aviesan.

Scientific Organizing Committee: John De Vos, Annelise Bennaceur-Griscelli, Cécile Martinat, François Hirsch and Armelle Regnault


Tuesday, November 25th

ESC / iPS Similitudes and differences

10h00-10h30    Reprogramming human and non-human primate embryonic stem cells to ground state pluripotency - Pierre Savatier (SBRI, Lyon)
10h30-11h00   X-chromosome inactivation in human pluripotent stem cells - Claire Rougeulle (Institut Epignétique, Paris)
11h00-11h30   iPSC and Ageing - Jean-Marc Lemaitre (IGF, Montpellier)
11h30-12h00   Lymphopoiesis modeling from hES cells - Rima Haddad (Inserm U967, U. Paris Sud, Fontenay aux Roses)
12h00-12h30   Christine Baldeschi (Nice)
12h30 - 14h   Lunch

National iPSC Infrastructure

14h-14h30   INGESTEM Large scale ipSC and International pluripotent stem cell Initiatives - Annelise Bennaceur (AP-HP, Inserm)

Production of iPS

14h30-14h50   Critical issues to produce GMP iPS cells - John De Vos (IRB, Montpellier)
14h50-15h10   CRISPR: genome engineering made easy - Olivier Féraud (ESTeam, Paris)
15h10-15h30   Bioprocessing of human pluripotent stem cells - Yacine Laabi (I Stem)

Ethical, legislative and regulatory situation

15h30-16h00   Ethics - Laure Coulombel (Agence de la Biomédecine)
16h00-16h30   EU support to stem cell research - Charles Kessler (Principal Scientific Officer, DGRI, European Commission)
16h30-17h00   Coffee break

Stem cells & Biomaterials

17h00-17h30   3D scaffolds for stem cells in vitro and in vivo - Didier Letourneur (LVTS, Paris)
17h30-18h00   Hematopoietic stem cell differentiation into platelet-producing megakaryocytes - Dominique Baruch (Inserm, Paris)

iPS for drug screening

18h00-18h30   Screening for neurogenesis modifiers using PSC-derived neuronal progenitors - Alexandra Benchoua (CECS/Istem, Evry)
18h30-19h00   Development of highly selective SMN2 splicing modifiers to find a therapy for spinal muscular atrophy - Friedrich Metzer (Roche Innovation Center, Basel)
20h   Dinner


Wednesday, November 26th

iPS as diseases and gene therapy models

9h00-9h30 Myeloproliferative disorders - Ali Turhan (Inserm, Le Kremlin Bicêtre)
9h30-10h00 Lentiviral globin gene transfer in beta-thalassemia iPS cell model - Leila Maouche-Chrétien (Inserm, Fontenay-aux-Roses)
10h00-10h30 Proof of concept for gene therapy in iPSC-derived retinal pigment epithelium from patients - Viki Kalatzis (INM, Montpellier)
10h30-11h00 Use of human pluripotent stem cells for neuromuscular diseases - Cécile Martinat (Istem, Evry)
11h-11h20 Coffee break
11h20-11h50 iPS to model neurodegenerative disorders - Delphine Bohl (ICM, Paris)
11h50-12h20 iPSC as a cellular model for epithelial physiopathology - Daniel Aberdam (Inserm, St Louis)
12h20-12h50 When neurodevelopment meets neurodegeneration: patient iPSC derived neurons to study a rare disorder - Matthias Groszer (Inserm)
12h50-14h00 Lunch

iPS use (autologous and allogenic)

14h00-14h30 Red blood cells from stem cells in vitro: perspectives for transfusion medicine - Luc Douay (Saint-Antoine, Paris)
14h30-15h00 Strategies working towards gene/cell therapy of liver diseases - Anne Dubart-Kupperschmitt (Inserm, Paul Brousse)
15h00-15h30     Optimized generation of neutrophils and macrophages from iPSC to model Chronic Granulomatous Disease - Marie José Stasia-Pauger (CNRS, UMR 5525, Université J. Fourier, Grenoble)
15h30-16h00 Coffee break
16h00-16h30 New type of endodermic stem cells for pancreatic and hepatic regeneration - Frank Griscelli (Inserm, Paris V)
16h30-17h00 Using human pluripotent stem cells to treat retinal disease - Olivier Goureau (Institut de la vision, Paris)

The end


Site par ID-Alizés